Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12 Giugno 2024 - 2:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D
(Rule 13d-101)
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(a) and Amendments Thereto Filed
Pursuant to § 240.13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 9)
Solid
Biosciences Inc.
(Name of Issuer)
Common Stock, $0.001
par value per share
(Title of Class of Securities)
83422E 105
(CUSIP
Number)
Bain Capital Life Sciences Investors, LLC
200 Clarendon Street
Boston, MA 02116
617-516-2000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 7, 2024
(Date of Event Which Requires Filing of This Statement)
If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note. Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
| CUSIP No. 83422E 105 |
|
13D |
|
Page
2
of 8 |
|
|
|
|
|
|
|
| 1 |
|
Names of reporting persons
BCLS SB Investco, LP |
| 2 |
|
Check the appropriate box if a
member of a group (a) ☐ (b) ☐
|
| 3 |
|
SEC use only
|
| 4 |
|
Source of funds
WC |
| 5 |
|
Check if disclosure of legal
proceedings is required pursuant to Item 2(d) or 2(e) ☐ |
| 6 |
|
Citizenship or place of
organization
Delaware |
|
|
|
|
|
|
|
| Number of
shares beneficially
owned by each
reporting person
with: |
|
7 |
|
Sole voting power
0 shares of Common Stock |
| |
8 |
|
Shared voting power
528,660 shares of Common Stock |
| |
9 |
|
Sole dispositive power
0 shares of Common Stock |
| |
10 |
|
Shared dispositive power
528,660 shares of Common
Stock |
|
|
|
|
|
|
|
| 11 |
|
Aggregate amount beneficially owned by each reporting person
528,660 shares of Common Stock |
| 12 |
|
Check if the aggregate amount
in Row (11) excludes certain shares ☐ |
| 13 |
|
Percent of class represented by
amount in Row (11) 1.4% |
| 14 |
|
Type of reporting person
PN |
|
|
|
|
|
| CUSIP No. 83422E 105 |
|
13D |
|
Page
3
of 8 |
|
|
|
|
|
|
|
| 1 |
|
Names of reporting persons
Bain Capital Life Sciences Fund II, L.P. |
| 2 |
|
Check the appropriate box if a
member of a group (a) ☐ (b) ☐
|
| 3 |
|
SEC use only
|
| 4 |
|
Source of funds
SC |
| 5 |
|
Check if disclosure of legal
proceedings is required pursuant to Item 2(d) or 2(e) ☐ |
| 6 |
|
Citizenship or place of
organization Cayman
Islands |
|
|
|
|
|
|
|
| Number of
shares beneficially
owned by each
reporting person
with: |
|
7 |
|
Sole voting power
0 shares of Common Stock |
| |
8 |
|
Shared voting power
267,257 shares of Common Stock |
| |
9 |
|
Sole dispositive power
0 shares of Common Stock |
| |
10 |
|
Shared dispositive power
267,257 shares of Common
Stock |
|
|
|
|
|
|
|
| 11 |
|
Aggregate amount beneficially owned by each reporting person
267,257 shares of Common Stock |
| 12 |
|
Check if the aggregate amount
in Row (11) excludes certain shares ☐ |
| 13 |
|
Percent of class represented by
amount in Row (11) 0.7% |
| 14 |
|
Type of reporting person
PN |
|
|
|
|
|
| CUSIP No. 83422E 105 |
|
13D |
|
Page
4
of 8 |
|
|
|
|
|
|
|
| 1 |
|
Names of reporting persons
BCLS II Investco, LP |
| 2 |
|
Check the appropriate box if a
member of a group (a) ☐ (b) ☐
|
| 3 |
|
SEC use only
|
| 4 |
|
Source of funds
WC, SC |
| 5 |
|
Check if disclosure of legal
proceedings is required pursuant to Item 2(d) or 2(e) ☐ |
| 6 |
|
Citizenship or place of
organization
Delaware |
|
|
|
|
|
|
|
| Number of
shares beneficially
owned by each
reporting person
with: |
|
7 |
|
Sole voting power
0 shares of Common Stock |
| |
8 |
|
Shared voting power
2,301,955 shares of Common Stock |
| |
9 |
|
Sole dispositive power
0 shares of Common Stock |
| |
10 |
|
Shared dispositive power
2,301,955 shares of Common
Stock |
|
|
|
|
|
|
|
| 11 |
|
Aggregate amount beneficially owned by each reporting person
2,301,955 shares of Common Stock |
| 12 |
|
Check if the aggregate amount
in Row (11) excludes certain shares ☐ |
| 13 |
|
Percent of class represented by
amount in Row (11) 6.0% |
| 14 |
|
Type of reporting person
PN |
|
|
|
|
|
| CUSIP No. 83422E 105 |
|
13D |
|
Page
5
of 8 |
|
|
|
|
|
|
|
| 1 |
|
Names of reporting persons
BCIP Life Sciences Associates, LP |
| 2 |
|
Check the appropriate box if a
member of a group (a) ☐ (b) ☐
|
| 3 |
|
SEC use only
|
| 4 |
|
Source of funds
SC |
| 5 |
|
Check if disclosure of legal
proceedings is required pursuant to Item 2(d) or 2(e) ☐ |
| 6 |
|
Citizenship or place of
organization
Delaware |
|
|
|
|
|
|
|
| Number of
shares beneficially
owned by each
reporting person
with: |
|
7 |
|
Sole voting power
0 shares of Common Stock |
| |
8 |
|
Shared voting power
32,550 shares of Common Stock |
| |
9 |
|
Sole dispositive power
0 shares of Common Stock |
| |
10 |
|
Shared dispositive power
32,550 shares of Common
Stock |
|
|
|
|
|
|
|
| 11 |
|
Aggregate amount beneficially owned by each reporting person
32,550 shares of Common Stock |
| 12 |
|
Check if the aggregate amount
in Row (11) excludes certain shares ☐ |
| 13 |
|
Percent of class represented by
amount in Row (11) Less than 0.1% |
| 14 |
|
Type of reporting person
PN |
|
|
|
|
|
| CUSIP No. 83422E 105 |
|
13D |
|
Page
6
of 8 |
|
|
|
|
|
|
|
| 1 |
|
Names of reporting persons
BCLS II Equity Opportunities, LP |
| 2 |
|
Check the appropriate box if a
member of a group (a) ☐ (b) ☐
|
| 3 |
|
SEC use only
|
| 4 |
|
Source of funds
WC |
| 5 |
|
Check if disclosure of legal
proceedings is required pursuant to Item 2(d) or 2(e) ☐ |
| 6 |
|
Citizenship or place of
organization
Delaware |
|
|
|
|
|
|
|
| Number of
shares beneficially
owned by each
reporting person
with: |
|
7 |
|
Sole voting power
0 shares of Common Stock |
| |
8 |
|
Shared voting power
904,160 shares of Common Stock |
| |
9 |
|
Sole dispositive power
0 shares of Common Stock |
| |
10 |
|
Shared dispositive power
904,160 shares of Common
Stock |
|
|
|
|
|
|
|
| 11 |
|
Aggregate amount beneficially owned by each reporting person
904,160 shares of Common Stock |
| 12 |
|
Check if the aggregate amount
in Row (11) excludes certain shares ☐ |
| 13 |
|
Percent of class represented by
amount in Row (11) 2.4% |
| 14 |
|
Type of reporting person
PN |
|
|
|
|
|
| CUSIP No. 83422E 105 |
|
13D |
|
Page
7
of 8 |
This Amendment No. 9 to Schedule 13D relates to the Common Stock of Solid Biosciences Inc. and amends
the initial statement on Schedule 13D filed by BCLS SB Investco, LP on February 1, 2018, as amended by Amendment No. 1 filed on July 30, 2019, Amendment No. 2 filed on December 11, 2020, Amendment No. 3 filed on
March 25, 2021, Amendment No. 4 filed on August 18, 2022, Amendment No. 5 filed on October 3, 2022, Amendment No. 6 filed on December 5, 2022, Amendment No. 7 filed on January 10, 2024 and Amendment
No. 8 filed on January 12, 2024 (the “Initial Statement” and, as further amended by this Amendment No. 9, the “Schedule 13D”). Capitalized terms used but not defined herein shall have the meanings ascribed to them
in the Initial Statement.
Item 4. Purpose of Transaction
Item 4 of the Initial Statement is hereby amended and supplemented to add the following:
On June 7, 2024, Adam Koppel, a Partner of BCLSI, tendered his resignation from the Issuer’s Board of Directors, effective as of June 11, 2024.
SIGNATURES
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true,
complete and correct.
|
|
|
|
|
|
|
| Dated: June 11, 2024 |
|
|
|
BCLS SB Investco, LP |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Partners, LP, its general partner |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors, LLC, its general partner |
|
|
|
|
|
|
|
|
By: |
|
/s/ Adam Koppel |
|
|
|
|
Name: |
|
Adam Koppel |
|
|
|
|
Title: |
|
Partner |
|
|
|
|
|
|
|
Bain Capital Life Sciences Fund II, L.P. |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors II, LLC, its general partner |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors, LLC, its manager |
|
|
|
|
|
|
|
|
By: |
|
/s/ Adam Koppel |
|
|
|
|
Name: |
|
Adam Koppel |
|
|
|
|
Title: |
|
Partner |
|
|
|
|
|
|
|
BCLS II Investco, LP |
|
|
|
|
|
|
|
By: BCLS II Investco (GP), LLC, its general partner |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Fund II, L.P., its managing member |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors II, LLC, its general partner |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors, LLC, its manager |
|
|
|
|
|
|
|
|
By: |
|
/s/ Adam Koppel |
|
|
|
|
Name: |
|
Adam Koppel |
|
|
|
|
Title: |
|
Partner |
|
|
|
|
|
|
|
BCIP Life Sciences Associates, LP |
|
|
|
|
|
|
|
By: Boylston Coinvestors, LLC, its general partner |
|
|
|
|
|
|
|
|
By: |
|
/s/ Adam Koppel |
|
|
|
|
Name: |
|
Adam Koppel |
|
|
|
|
Title: |
|
Authorized Signatory |
|
|
|
|
|
|
|
BCLS II Equity Opportunities, LP |
|
|
|
|
|
|
|
By: BCLS II Equity Opportunities GP, LLC, its general partner |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Fund II, L.P., its manager |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors II, LLC, its general partner |
|
|
|
|
|
|
|
By: Bain Capital Life Sciences Investors, LLC, its manager |
|
|
|
|
|
|
|
|
By: |
|
/s/ Adam Koppel |
|
|
|
|
Name: |
|
Adam Koppel |
|
|
|
|
Title: |
|
Partner |
Grafico Azioni Solid Biosciences (NASDAQ:SLDB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Solid Biosciences (NASDAQ:SLDB)
Storico
Da Dic 2023 a Dic 2024
